Nateglinide: a double blind add-on study with pioglitazone for type 2 diabetic patients

Trial Profile

Nateglinide: a double blind add-on study with pioglitazone for type 2 diabetic patients

Completed
Phase of Trial: Phase II/III

Latest Information Update: 14 Dec 2006

At a glance

  • Drugs Nateglinide (Primary) ; Pioglitazone
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 14 Dec 2006 Status change
    • 11 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top